The Zika virus, which originated in the Zika forest in Uganda, has now infected humans around the world, causing fevers and rashes along with more serious nervous system complications such as Guillain-Barre syndrome and microcephaly. U.S. service members and their families are at higher risk for Zika virus infection than the general U.S. population as they often deploy to areas with active transmission of Zika. In an unprecedented 180 days, USAMRMC and WRAIR developed a Zika purified inactivated virus (ZPIV) vaccine candidate and published preclinical findings in Nature and Science. Three initial ZPIV human trials began in 2016, each addressing a unique question about background immunity, vaccine dose or vaccination schedule. The results of these trials, published in November 2017, showed that the vaccine induced a robust immune response and was safe and well-tolerated in healthy adults. A fourth ZPIV trial is still underway in Puerto Rico, where the population has natural exposure to other viruses in the same family as Zika, such as dengue. (Figure courtesy of USAMRMC)
| Date Taken: | 01.01.2018 |
| Date Posted: | 02.12.2018 13:01 |
| Photo ID: | 4135895 |
| VIRIN: | 180212-A-N1234-033 |
| Resolution: | 2400x534 |
| Size: | 190.45 KB |
| Location: | US |
| Web Views: | 50 |
| Downloads: | 9 |
This work, Zika virus vaccine [Image 12 of 12], must comply with the restrictions shown on https://www.dvidshub.net/about/copyright.
Investing in Army laboratory innovation
No keywords found.
